Contemporary murine models in preclinical astrocytoma drug development

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.

(2017) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutant IDH1 is required for IDH1 mutated tumor cell growth

(2015) Genglin Jin et al.   Oncotarget

LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program

(2015) Xing-gang Mao et al.   Oncotarget

Abstract C81: BBB efflux pump activity limits brain penetration of palbociclib (PD0332991) in glioblastoma.

(2014) K. E. Parrish et al.   MOLECULAR CANCER THERAPEUTICS

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

(2014) A. P. Patel et al.   SCIENCE

Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach

(2013) Markus J. Riemenschneider et al.   ACTA NEUROPATHOLOGICA

Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?

(2013) T C Hirst et al.   BRITISH JOURNAL OF CANCER

Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma

(2013) Krishna P.L. Bhat et al.   CANCER CELL

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition

(2013) Y. Piao et al.   CLINICAL CANCER RESEARCH

The evolving landscape of glioblastoma stem cells

(2013) Kenneth Yan et al.   CURRENT OPINION IN NEUROLOGY

Medulloblastoma molecular dissection

(2013) Marc Remke et al.   CURRENT OPINION IN ONCOLOGY

New cast for a new era: preclinical cancer drug development revisited

(2013) Grit S. Herter-Sprie et al.   JOURNAL OF CLINICAL INVESTIGATION

Personalizing Oncology: Perspectives and Prospects

(2013) John Mendelsohn   JOURNAL OF CLINICAL ONCOLOGY

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

The causes and consequences of genetic heterogeneity in cancer evolution

(2013) Rebecca A. Burrell et al.   NATURE

The integrated landscape of driver genomic alterations in glioblastoma

(2013) Veronique Frattini et al.   NATURE GENETICS

Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities

(2013) Mariella Gruber Filbin et al.   NATURE MEDICINE

Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis

(2013) M. Vitucci et al.   NEURO-ONCOLOGY

Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop

(2013) Jason T. Huse et al.   NEURO-ONCOLOGY

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models

(2013) Ling Cen et al.   NEURO-ONCOLOGY

Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2

(2013) B. M. Alexander et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

(2013) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Akt and c-Myc Induce Stem-Cell Markers in Mature Primary p53−/− Astrocytes and Render These Cells Gliomagenic in the Brain of Immunocompetent Mice

(2013) Josefine Radke et al.   PLoS One

A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1

(2013) Barbara Klink et al.   PLoS One

High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models

(2013) Shawn E. Yost et al.   PLoS One

Evolutionary etiology of high-grade astrocytomas

(2013) Y. Song et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

(2013) A. Sottoriva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

Patient-Specific Orthotopic Glioblastoma Xenograft Models Recapitulate the Histopathology and Biology of Human Glioblastomas In Situ

(2013) Kyeung Min Joo et al.   Cell Reports

Glioblastoma: Molecular Analysis and Clinical Implications

(2012) Jason T. Huse et al.   Annual Review of Medicine

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

(2012) L. Burt Nabors et al.   CANCER

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

(2012) Yosuke Togashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Glioblastoma Cancer Stem-Like Cells

(2012) Edjah Kweku-Ebura Nduom et al.   CANCER JOURNAL

Gliomagenesis Arising from Pten- and Ink4a/Arf-Deficient Neural Progenitor Cells Is Mediated by the p53-Fbxw7/Cdc4 Pathway, Which Controls c-Myc

(2012) H. S. Kim et al.   CANCER RESEARCH

Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas

(2012) G. Jin et al.   CANCER RESEARCH

Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells

(2012) Jian Chen et al.   CELL

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

(2012) James S. Duncan et al.   CELL

Matching mice to malignancy: molecular subgroups and models of medulloblastoma

(2012) Jasmine Lau et al.   CHILDS NERVOUS SYSTEM

Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

(2012) G. J. Kitange et al.   CLINICAL CANCER RESEARCH

Targeting the PI3K Pathway in the Brain--Efficacy of a PI3K Inhibitor Optimized to Cross the Blood-Brain Barrier

(2012) L. Salphati et al.   CLINICAL CANCER RESEARCH

IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma

(2012) D. Gorovets et al.   CLINICAL CANCER RESEARCH

D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function

(2012) M. Sasaki et al.   GENES & DEVELOPMENT

Emerging insights into the molecular and cellular basis of glioblastoma

(2012) G. P. Dunn et al.   GENES & DEVELOPMENT

A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation

(2012) C. G. Duncan et al.   GENOME RESEARCH

Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma

(2012) Lorenzo Trippa et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Production of avian retroviruses and tissue-specific somatic retroviral gene transfer in vivo using the RCAS/TVA system

(2012) Alexander von Werder et al.   Nature Protocols

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

The clinical implications of medulloblastoma subgroups

(2012) Paul A. Northcott et al.   Nature Reviews Neurology

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation

(2012) Sichen Li et al.   NEURO-ONCOLOGY

In vivo models of primary brain tumors: pitfalls and perspectives

(2012) P. C. Huszthy et al.   NEURO-ONCOLOGY

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

(2012) Igor Vivanco et al.   Cancer Discovery

Glioblastoma: From Molecular Pathology to Targeted Treatment

(2011) Timothy F. Cloughesy et al.   Annual Review of Pathology-Mechanisms of Disease

Genetically engineered mouse models of diffuse gliomas

(2011) Ralf S. Schmid et al.   BRAIN RESEARCH BULLETIN

Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions

(2011) S Piaskowski et al.   BRITISH JOURNAL OF CANCER

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma

(2011) Matija Snuderl et al.   CANCER CELL

Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult Brain

(2011) Lionel M.L. Chow et al.   CANCER CELL

Mosaic Analysis with Double Markers Reveals Tumor Cell of Origin in Glioma

(2011) Chong Liu et al.   CELL

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

(2011) Sagar Agarwal et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Genetic modeling of gliomas in mice: New tools to tackle old problems

(2011) Dolores Hambardzumyan et al.   GLIA

Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients

(2011) Sameer Agnihotri et al.   JOURNAL OF CLINICAL INVESTIGATION

The neurobiology of gliomas: from cell biology to the development of therapeutic approaches

(2011) Manfred Westphal et al.   NATURE REVIEWS NEUROSCIENCE

A multigene predictor of outcome in glioblastoma

(2011) H. Colman et al.   NEURO-ONCOLOGY

An in vivo patient-derived model of endogenous IDH1-mutant glioma

(2011) H. A. Luchman et al.   NEURO-ONCOLOGY

Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM

(2011) Y.-W. Kim et al.   NEURO-ONCOLOGY

Report from the Fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop

(2011) D. H. Gutmann et al.   NEURO-ONCOLOGY

Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme

(2011) H J Jun et al.   ONCOGENE

Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma

(2011) Kenneth L. Pitter et al.   PLoS One

Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy

(2010) M Vitucci et al.   BRITISH JOURNAL OF CANCER

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors

(2010) B. McEllin et al.   CANCER RESEARCH

Transcriptional Profiles of CD133+ and CD133- Glioblastoma-Derived Cancer Stem Cell Lines Suggest Different Cells of Origin

(2010) C. Lottaz et al.   CANCER RESEARCH

Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies

(2010) N. A. de Vries et al.   CLINICAL CANCER RESEARCH

Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074

(2010) Joon H. Uhm et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

(2010) Nienke A. de Vries et al.   INVESTIGATIONAL NEW DRUGS

Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain

(2010) Claudia R. Oliva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

The Novel Hsp90 Inhibitor NXD30001 Induces Tumor Regression in a Genetically Engineered Mouse Model of Glioblastoma Multiforme

(2010) H. Zhu et al.   MOLECULAR CANCER THERAPEUTICS

Oligodendroglioma cell lines containing t(1;19)(q10;p10)

(2010) J. J. P. Kelly et al.   NEURO-ONCOLOGY

U87MG Decoded: The Genomic Sequence of a Cytogenetically Aberrant Human Cancer Cell Line

(2010) Michael James Clark et al.   PLoS Genetics

Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting

(2010) Zhi Huang et al.   Protein & Cell

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

(2009) Brian Thiessen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

High-grade glioma mouse models and their applicability for preclinical testing

(2009) Nienke A. de Vries et al.   CANCER TREATMENT REVIEWS

Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma

(2009) J.-S. Guillamo et al.   CLINICAL CANCER RESEARCH

Radiosensitizing Effects of Temozolomide Observed in vivo only in a Subset of O6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts

(2009) Brett L. Carlson et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

(2009) David M. Peereboom et al.   JOURNAL OF NEURO-ONCOLOGY

Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas

(2009) Rolf F. Barth et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

(2009) M. J. Clarke et al.   MOLECULAR CANCER THERAPEUTICS

The transcriptional network for mesenchymal transformation of brain tumours

(2009) Maria Stella Carro et al.   NATURE

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

(2009) Bin-Bing S. Zhou et al.   NATURE REVIEWS DRUG DISCOVERY

Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts

(2009) J. Graeme Hodgson et al.   NEURO-ONCOLOGY

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 

(2009) S. Zhao et al.   SCIENCE

Oncogenic EGFR Signaling Networks in Glioma

(2009) P. H. Huang et al.   Science Signaling

Genetically Engineered Mouse Models of Brain Cancer and the Promise of Preclinical Testing

(2008) Jason T. Huse et al.   BRAIN PATHOLOGY

p53 Small-Molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts

(2008) E. B. Dinca et al.   CANCER RESEARCH

Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments

(2008) A. A. Brandes et al.   CLINICAL CANCER RESEARCH

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency

(2008) Tom Mikkelsen et al.   INTERNATIONAL JOURNAL OF CANCER

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

(2008) Paul D. Brown et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

(2008) Michael D. Prados et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma

(2008) S. Amarasingh et al.   JOURNAL OF NEURO-ONCOLOGY

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model

(2008) Gaspar J. Kitange et al.   JOURNAL OF NEURO-ONCOLOGY

From Human to Mouse and Back: 'Tumorgraft' Models Surge in Popularity

(2008) K. Garber   JNCI-Journal of the National Cancer Institute

Genomic Changes and Gene Expression Profiles Reveal That Established Glioma Cell Lines Are Poorly Representative of Primary Human Gliomas

(2008) A. Li et al.   MOLECULAR CANCER RESEARCH

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

New (alternative) temozolomide regimens for the treatment of glioma

(2008) Wolfgang Wick et al.   NEURO-ONCOLOGY

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

(2008) Gaspar J. Kitange et al.   NEURO-ONCOLOGY